What is Neumora Therapeutics, Inc. Common Stock (NMRA)?

Neumora Therapeutics, Inc. Common Stock (NMRA) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of NMRA?

The current price of NMRA is $0.37. Prices are updated in real time on Stocks360.

What is NMRA's price-to-earnings (PE) ratio?

NMRA's trailing twelve-month PE ratio is -0.30, based on current price and earnings per share data available on Stocks360.

What is NMRA's market capitalization?

NMRA's market capitalization is $68,995,374.00, placing it in the small-cap tier.

Neumora Therapeutics, Inc. Common Stock (NMRA)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.37

Market Cap

$69.00M

PE (TTM)

-0.30

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.98

Day Range

$0.35 – $0.41

52-wk Range

$0.32 – $3.65

Avg Volume

N/A

Volume

1.11M

Neumora Therapeutics, Inc. Common Stock (NMRA) is a publicly traded company in the Healthcare sector. Latest price: $0.37. Market cap $69.00M. Trailing PE -0.30. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $3.02 2026-10-30 · $0.37 (-87.84%)

Earnings

Most Recent

Aug 14, 2026

EPS $-0.23 vs est. $-0.24

Beat by $0.01

Next Earnings

Nov 5, 2026

EPS estimate $-0.19

Proprietary Signals

Signal snapshot temporarily unavailable.

About Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 202…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.30×
P/S (TTM)	0.00×
P/B	1.53×
P/FCF (TTM)	-0.38×
EV / EBITDA	0.23×
EV / Sales	0.00×
Earnings Yield	-312.90%
Free Cash Flow Yield	-261.64%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$47.50M
Net Income (TTM)	-$215.88M
Free Cash Flow (TTM)	-$174.06M
Net Debt	-$116.49M
Working Capital	$97.10M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-242.28%
Return on Invested Capital	-216.05%